Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GH Secretagogue

Ipamorelin vs Tesamorelin

Ipamorelin and Tesamorelin target complementary receptors in the GH-release pathway. Ipamorelin is a selective ghrelin-receptor agonist. Tesamorelin is an FDA-approved GHRH analog. Together they form one of the cleanest evidence-supported GH-secretagogue stacks.

Bangkok research desk ·

Side-by-side

Ipamorelin Tesamorelin
MechanismSelective GHS-R1a; minimal cortisol or prolactin effect.GHRH analog; FDA-approved; preserves pulsatility.
Half-life~2 hours.Short plasma.
Dose200-300 mcg × 2-3 daily SC.1-2 mg daily SC.
Cycle12 weeks on / 4 off.12 weeks on / 4 off (research); continuous clinical use.
Research contextSelective GH release1.FDA-approved for HIV visceral adiposity; metabolic endpoints2.
Cost tierLow-to-mid.High.

Ipamorelin and Tesamorelin are often compared because researchers want to know which to pair with which. Both are clean, both have good safety profiles, and both drive measurable IGF-1 elevation. The mechanistic difference is which half of the GH-release pathway they target: Ipamorelin works at the ghrelin receptor on pituitary somatotrophs1; Tesamorelin works at the GHRH receptor2.

The complementarity is why they stack well. Using Ipamorelin alongside Tesamorelin produces a GH output that approximates physiological pulsatility better than either alone: Tesamorelin provides the GHRH tone the pituitary responds to, and Ipamorelin amplifies the ghrelin-mediated pulse that completes the natural pattern. Dose timing typically places Tesamorelin as a single evening injection (its clinical-use pattern) and Ipamorelin at 2-3 split daily doses around training or meals.

Standalone selection usually turns on clinical-registration context. A researcher running a visceral-adiposity protocol with evidence-grade comparator data selects Tesamorelin. A researcher running a GH-pulse study on a research-grade budget selects Ipamorelin. When both are available, pairing them is the default in the literature, because the mechanisms complement without overlap. See the GH secretagogue cycle design and Tesamorelin clinical history.

Frequently asked

Is pairing Ipamorelin with Tesamorelin better than Ipamorelin alone?
In research protocols that want GH output approximating physiological pulsatility, yes. The two compounds target different receptors and produce additive rather than redundant stimulation. Ipamorelin alone produces pulses without elevated GHRH tone.
Can this stack replace CJC-1295 + Ipamorelin?
Functionally yes, because Tesamorelin and CJC-1295 both activate the GHRH receptor. The practical differences are dosing frequency (Tesamorelin daily vs CJC-1295 weekly) and clinical-registration context (Tesamorelin is FDA-approved).
What is the cycle length?
12 weeks on / 4 off is the standard research-protocol cycle for both compounds individually. The stack follows the same pattern.
Research desk
Ordering both Ipamorelin and Tesamorelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
  2. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PMID: 18057338

All references verified against PubMed via NCBI E-utilities.